跳至主要内容
临床试验/EUCTR2014-003002-32-AT
EUCTR2014-003002-32-AT进行中(未招募)1 期

Open label study to evaluate the pharmacokinetics of fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects with Clostridium difficile Infection (CDI) - PROFILE

Astellas Pharma Europe Ltd.0 个研究点目标入组 25 人开始时间: 2015年4月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ? Subject is aged at least 18
  • ? Confirmed diagnosis or history of IBD for at least 3 months
  • ? CDI confirmed positive according to local standard testing for the presence of C. difficile within 48 hr prior to enrolment.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Subject has received more than one day of dosing of any CDI therapy within the 48 hrs prior to enrolment.
  • Presence of an ostomy or short bowel syndrome
  • Subject has a current diagnosis of toxic megacolon
  • Subject has previously participated in a CDI vaccine study
  • Subject has hypersensitivity to fidaxomicin or any of its components

研究者

相似试验

进行中(未招募)
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.
EUCTR2014-003002-32-PLAstellas Pharma Europe Ltd.40
进行中(未招募)
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concommitantly an infection of the gut caused by bacteria called Clostridium difficile.
EUCTR2014-003002-32-GRAstellas Pharma Europe Ltd.40
进行中(未招募)
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 18.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862
EUCTR2014-003002-32-CZAstellas Pharma Europe Ltd.40
进行中(未招募)
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studiedin patients with an inflammation of the intestine and concommitantly aninfection of the gut caused by bacteria called Clostridium difficile.
EUCTR2014-003002-32-ITASTELLAS PHARMA EUROPE LIMITED25
进行中(未招募)
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concommitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 18.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862
EUCTR2014-003002-32-DEAstellas Pharma Europe Ltd.40